Triple antithrombotic therapy versus double antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients requiring chronic oral anticoagulation: A meta-analysis

Chinese Medical Journal

Volumn 126, Issue 13, 2013, Pages 2536-2542

  Saheb, K Jayswal ^a   Deng, Bing Qing ^a   Hu, Qing Song ^a   Xie, Shuang Lun ^a   Geng, Deng Feng ^a   Nie, Ru Qiong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chronic oral anticoagulation; Double antiplatelet therapy; Meta analysis; Percutaneous coronary intervention; Triple antithrombotic therapy

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ARTICLE; BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR STENT; DATA EXTRACTION; DISEASE ASSOCIATION; ELECTROCARDIOGRAPHY; HEART INFARCTION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PUBLISHING; STENT THROMBOSIS;

AGED; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PUBLICATION BIAS; STENTS;

EID: 84879734992     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20130359     Document Type: Article

References (40)

1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the american college of cardiology/ american heart association task force on practice guidelines and the european society of cardiology committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation). Eur Heart J 2006; 27: 1979-2030.
2. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB, et al. Acc/aha/scai 2005 guideline update for percutaneous coronary intervention--summary article: a report of the american college of cardiology/american heart association task force on practice guidelines (acc/aha/scai writing committee to update the 2001 guidelines for percutaneous coronary intervention). Circulation 2006; 113: 156-175.
3. Karjalainen PP, Porela P, Ylitalo A, Vikman S, Nyman K, Vaittinen MA, et al. Safety and efficacy of combined antiplateletwarfarin therapy after coronary stenting. Eur Heart J. 2007; 28: 726-732.
4. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118: 2029-2037.
5. Gao F, Zhou YJ, Wang ZJ, Shen H, Liu XL, Nie B, et al. Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation. Circ J 2010; 74: 701-708.
6. Zhao HJ, Zheng ZT, Wang ZH, Li SH, Zhang Y, Zhong M, et al. "Triple therapy" rather than "triple threat": a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest 2011; 139: 260-270.
7. Orford JL, Fasseas P, Melby S, Burger K, Steinhubl SR, Holmes DR, et al. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 2004; 147: 463-467.
8. Rogacka R, Chieffo A, Michev I, Airoldi F, Latib A, Cosgrave J, et al. Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation. JACC Cardiovasc Interv 2008; 1: 56-61.
9. Rubboli A, Colletta M, Herzfeld J, Sangiorgio P, Di Pasquale G. Periprocedural and medium-term antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary angiography and intervention. Coron Artery Dis 2007; 18: 193-199.
10. Nguyen MC, Lim YL, Walton A, Lefkovits J, Agnelli G, Goodman SG, et al. Combining warfarin and antiplatelet therapy after coronary stenting in the global registry of acute coronary events: Is it safe and effective to use just one antiplatelet agent? Eur Heart J 2007; 28: 1717-1722.
11. Guasch E, Sionis A, Reverter JC, Andrea R, Loma-Osorio P, Freixa X, et al. Safety issues of adjunctive clopidogrel in patients discharged after percutaneous coronary intervention with stent placement and requiring oral anticoagulation. Int J Cardiol 2011; 146: e1-e4.
12. Persson J, Lindback J, Hofman-Bang C, Lagerqvist B, Stenestrand U, Samnegard A. Efficacy and safety of clopidogrel after pci with stenting in patients on oral anticoagulants with acute coronary syndrome. EuroIntervention 2011; 6: 1046-1052, 1048-1049.
13. Wang TY, Robinson LA, Ou FS, Roe MT, Ohman EM, Gibler WB, et al. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: Physician practice in the crusade registry. Am Heart J 2008; 155: 361-368.
14. Lip GY, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: The need for consensus and a management guideline. Chest 2006; 130: 1823-1827.
15. Halbfass P, Janko S, Dorwarth U, Riess G, Antoni D, Hoffmann E. Dilemma of antithrombotic therapy in anticoagulated atrial fibrillation patients squeezed between thrombosis and bleeding events: a single-centre experience. Europace 2009; 11: 957-960.
16. Rubboli A, Colletta M, Sangiorgio P, Di Pasquale G. Antithrombotic strategies in patients with an indication for longterm anticoagulation undergoing coronary artery stenting: Safety and efficacy data from a single center. Ital Heart J 2004; 5: 919-925.
17. Sambola A, Ferreira-Gonzalez I, Angel J, Alfonso F, Maristany J, Rodriguez O, et al. Therapeutic strategies after coronary stenting in chronically anticoagulated patients: The musica study. Heart 2009; 95: 1483-1488.
18. Konstantino Y, Iakobishvili Z, Porter A, Sandach A, Zahger D, Hod H, et al. Aspirin, warfarin and a thienopyridine for acute coronary syndromes. Cardiology 2006; 105: 80-85.
19. Khurram Z, Chou E, Minutello R, Bergman G, Parikh M, Naidu S, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol 2006; 18: 162-164.
20. DeEugenio D, Kolman L, DeCaro M, Andrel J, Chervoneva I, Duong P, et al. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. Pharmacotherapy 2007; 27: 691-696.
21. Rossini R, Musumeci G, Lettieri C, Molfese M, Mihalcsik L, Mantovani P, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol 2008; 102: 1618-1623.
22. Olson KL, Delate T, Johnson SG, Wilson ED, Witt DM. Incidence of hemorrhage among anticoagulated patients receiving antiplatelet therapy after percutaneous coronary intervention. J Thromb Thrombolysis 2010; 29: 316-321.
23. Uchida Y, Mori F, Ogawa H, Takagi A, Hagiwara N. Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents. J Cardiol 2010; 55: 362-369.
24. Rubboli A, Magnavacchi P, Guastaroba P, Saia F, Vignali L, Giacometti P, et al. Antithrombotic management and 1-year outcome of patients on oral anticoagulation undergoing coronary stent implantation (from the registro regionale angioplastiche emilia-romagna registry). Am J Cardiol 2012; 109: 1411-1417.
25. Ruiz-Nodar JM, Marin F, Hurtado JA, Valencia J, Pinar E, Pineda J, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 2008; 51: 818-825.
26. Mattichak SJ, Reed PS, Gallagher MJ, Boura JA, O'Neill WW, Kahn JK. Evaluation of safety of warfarin in combination with antiplatelet therapy for patients treated with coronary stents for acute myocardial infarction. J Interv Cardiol 2005; 18: 163-166.
27. Gilard M, Blanchard D, Helft G, Carrier D, Eltchaninoff H, Belle L, et al. Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from stenting and oral anticoagulants [stentico]). Am J Cardiol 2009; 104: 338-342.
28. Maegdefessel L, Schlitt A, Faerber J, Bond SP, Messow CM, Buerke M, et al. Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. A single-center experience. Med Klin (Munich) 2008; 103: 628-632.
29. Manzano-Fernandez S, Pastor FJ, Marin F, Cambronero F, Caro C, Pascual-Figal DA, et al. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest 2008; 134: 559-567.
30. Sarafoff N, Ndrepepa G, Mehilli J, Dorrler K, Schulz S, Iijima R, et al. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. J Intern Med 2008; 264: 472-480.
31. Fosbol EL, Wang TY, Li S, Piccini JP, Lopes RD, Shah B, et al. Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-st elevation myocardial infarction. Am Heart J 2012; 163: 720-728.
32. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the esc guidelines for the management of atrial fibrillation: An update of the 2010 esc guidelines for the management of atrial fibrillation * developed with the special contribution of the european heart rhythm association. Europace 2012; 14: 1385-1413.
33. Apostolakis S, Shantsila E, Lip GY, Lane DA. Contra: "Antiplatelet therapy is an alternative to oral anticoagulation for atrial fibrillation". Thromb Haemost 2009; 102: 914-915.
34. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007; 297: 159-168.
35. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030-1039.
36. Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103: 13-28.
37. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the european society of cardiology (esc). Eur Heart J 2010; 31: 2369-2429.
38. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. N Engl J Med 2011; 365: 883-891.
39. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. N Engl J Med 2011; 365: 981-992.
40. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.